
Number of publications published per year by Ledermann, Monika. (Source : PubMed)

Distribution of publications types for Ledermann, Monika. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.
Hepatology
2009;50;5
Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2.
J Drug Target
2007;15;9

Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis.
Liver Int.
2007;27;6
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.
J. Hepatol.
2006;45;6

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.
J. Hepatol.
2006;44;1
Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice.
Liver Int.
2005;25;5
Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice.
J. Hepatol.
2004;40;2
Extended preservation of rat liver graft by induction of heme oxygenase-1.
Hepatology
2002;35;5
Relationship between hepatic mitochondrial functions in vivo and in vitro in rats with carbon tetrachloride-induced liver cirrhosis.
J. Hepatol.
2000;33;2
[ See timeline ] [ See all publications ]
means that Ledermann, Monika has 11 papers cited a least 11 times - methodology
Institute of Pathology, University of Bern, Bern, Switzerland.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.